ADT |
androgen deprivation therapy |
AGC |
protein kinase A, G and C families |
AKT |
protein kinase B |
AR-FL |
androgen receptor full length |
AR-V |
androgen receptor splice variants |
AR |
androgen receptor |
ARA |
androgen receptor antagonist |
ARE |
androgen response element |
ARSI |
androgen receptor signaling inhibitor |
ATP |
adenosine triphosphate |
BAD |
Bcl-2-associated death promoter |
BAT |
bipolar androgen therapy |
CRPC |
castration-resistant prostate cancer |
CSPC |
castration-sensitive prostate cancer |
CTC |
circulating tumor cells |
CTD |
hydrophobic regulatory motif domain |
CTLA4 |
cytotoxic T-lymphocyte-associated protein 4 |
CYP17A1 |
cytochrome P450 17α-hydroxylase/17,20-lyase |
DBD |
DNA-binding domain |
DHEA |
dehydroepiandrosterone |
DHT |
5α-dihydrotestosterone |
DNA |
deoxyribonucleic acid |
FDA |
Food and Drug Administration |
FISH |
fluorescence in situ hybridization |
FKBP5 |
FK506 binding protein 5 |
FOXO |
forkhead box transcription factors |
FSH |
follicle-stimulating hormone |
GnRH |
gonadotropin-releasing hormone |
GPCR |
G-protein-coupled receptor |
GSK 3 |
glycogen synthase kinase 3 |
HER |
human epidermal growth factor receptor |
HPG |
hypothalamus–pituitary–gonadal axis |
HSP |
heat-shock protein |
iNOS |
inducible nitric oxide synthase |
KO |
knockout |
LBD |
ligand-binding domain |
LH |
luteinizing hormone |
LHRH |
luteinizing hormone-releasing hormone |
LNCaP |
androgen-sensitive human prostate adenocarcinoma cells |
mCRPC |
metastatic castration-resistant prostate cancer |
mCSPC |
metastatic castration-sensitive prostate cancer |
mRNA |
messenger ribonucleic acid |
mTOR |
mammalian target of rapamycin |
mTORC1/2 |
mTOR complex ½ |
nmCRPC |
non metastatic castration-resistant prostate cancer |
NOS |
nitric oxide synthase |
NTD |
amino-terminal transcriptional domain |
OS |
overall survival |
p70S6K |
p70S6 kinase |
PARP |
poly ADP-ribose polymerase |
PCa |
prostate cancer |
PCR |
polymerase chain reaction |
PD-L1 |
programmed death-ligand 1 |
PD1 |
programmed cell death protein 1 |
PDK1 |
phosphoinositide-dependent kinase 1 |
PFS |
progression-free survival |
PH |
pleckstrin homology domain |
PHLPP |
PH domain of leucine repeat sequence-rich phosphatase |
PI(3,4)P2 |
phosphatidylinositol-3,4-biphosphate |
PI(4,5)P2 |
phosphatidylinositol-4,5-biphosphate |
PI3K |
phosphatidylinositol-3-kinase |
PIP3 |
phosphatidylinositol-3,4,5-triphosphate |
PKA |
protein kinase A |
PSA |
prostate-specific antigen |
PTEN |
phosphatase and tensin homolog |
RANKL |
receptor activator of nuclear factor kappa-B ligand |
RICTOR |
rapamycin-insensitive companion of mTOR |
RNA |
ribonucleic acid |
RP |
radical prostatectomy |
rPFS |
radiographic progression-free survival |
RT-PCR |
real time polymerase chain reaction |
RT |
radiotherapy |
RTK |
receptor tyrosine kinase |
SHBG |
sex hormone-binding globulin |
TSC 2 |
tuberosis sclerosis complex 2 |
Vps34 |
vacuolar protein signal 34 |